Abstract: The present invention relates to a composition comprising liposomes, wherein the liposomes preferably comprise phospholipids, magnetic nanoparticles, an imaging agent and an imaging label, and at least one active agent. The liposomes are capable of releasing the at least one active agent into a target environment by the concomitant action of a phospholipase that is able to degrade at least one of said one or more phospholipids and an alternating magnetic field.
Abstract: The present invention relates to nutrition for infants and young children with particular lipid globules, resulting in programming the metabolism to an increased energy expenditure and improved mitochondrial functioning later in life when exposed to a high fat, high energy diet.
Type:
Application
Filed:
September 8, 2016
Publication date:
June 1, 2017
Applicant:
N.V. Nutricia
Inventors:
Annemarie OOSTING, Francina Dorothea KODDE, Marieke ABRAHAMSE-BERKEVELD, Eline Marleen VAN DER BEEK
Abstract: Disclosed are particles comprising pectin and gelatin. The particles may be useful for preparing any of a variety products such as, for example, soft pharmaceutical capsules, hard pharmaceutical capsules, and foodstuffs. Also disclosed are methods for preparing the particles, the method comprising: (a) dissolving pectin in an aqueous solution to produce an aqueous solution of dissolved pectin; (b) mixing the aqueous solution of dissolved pectin with liquid gelatin to produce a gelatin/pectin mixture; (c) drying the gelatin/pectin mixture; and (d) milling the gelatin/pectin mixture to produce the plurality of particles.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
John M. DOLPHIN, Michelle A. MONTGOMERY
Abstract: This invention is a novel pharmaceutical composition comprising loxoprofen or a pharmaceutically acceptable salt thereof in combination with gamma-aminobutiric acid receptor agonist or a pharmaceutically acceptable salt thereof with anti-inflammatory, analgesic and myorelaxant activity.
Abstract: It has been desired to develop a coating composition, which is used for an orally-administered preparation having an improved administering property, and/or an easily administrable preparation that does not affect dissolution property. The present invention provides a coating composition comprising: a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate; and sucralose.
Type:
Application
Filed:
January 31, 2017
Publication date:
June 1, 2017
Applicant:
Mochida Pharmaceutical Co., Ltd.
Inventors:
Yumio KUDOU, Kuniomi WARABINO, Hiromitsu ITO
Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
Type:
Application
Filed:
July 6, 2016
Publication date:
June 1, 2017
Inventors:
Thomas Najarian, Peter Y. Tam, Leland F. Wilson
Abstract: Stable nanoparticle compositions comprising buprenorphine and at least one biodegradable polymer. The disclosure also provides methods of controlling pain in an animal and methods of treating addiction in a human utilizing the stable nanoparticle compositions, as well as pharmaceutical formulations comprising the stable nanoparticle compositions. The stable nanoparticle compositions are capable of releasing buprenorphine over several days, weeks, or months following administration. The stable nanoparticle compositions of buprenorphine utilize biodegradable polymers capable of degrading into non-toxic components in the body of an animal and may be excreted in the urine of the animal following their metabolism in the body. The stable nanoparticle compositions can advantageously provide sustained release of buprenorphine in the body after a single administration without the need for surgical removal of implanted matrices subsequent to depletion of the drug.
Abstract: The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.
Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 9, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Inventors:
Gregory T. WENT, Gayatri SATHYAN, Kavita VERMANI, Gangadhara GANAPATI, Michael COFFEE, Efraim SHEK, Ashok KATDARE
Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Type:
Application
Filed:
December 14, 2016
Publication date:
June 1, 2017
Inventors:
Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
Abstract: Disclosed is a method of treating Parkinson's disease and/or depression, and motor symptoms, non motor symptoms and depression symptoms associated with Parkinson's disease in a subject in need thereof, the method including administering to said subject a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, wherein the administering is effected by intranasal administration, and wherein a daily dose of the rasagiline or pharmaceutically acceptable salt thereof in the pharmaceutical composition is sufficient to inhibit monoamine oxidase (MAO)-A and MAO-B in a brain but insufficient to inhibit systemic MAO-A and therefore does not potentiate sympathetic cardiovascular activity associated with tyramine rich food consuming.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Inventors:
Moussa B.H. YOUDIM, Orly WEINREB, Tamar AMIT
Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its firmation to its administration.
Type:
Application
Filed:
May 12, 2015
Publication date:
June 1, 2017
Inventors:
David Devos, Caroline Moreau, Charlotte Laloux, Jean-christophe Devedjian
Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Applicants:
THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
Abstract: The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.
Abstract: The present invention relates to novel uses of a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, in treating a disorder associated with the PPP1R15A pathway and associated with protein misfolding stress and in particular with accumulation of misfolded proteins selected in the group of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, lysosomal storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, ischemia.
Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
Abstract: An organ protectant solution which is intravenously administered includes at least one oncotic agent and optionally a high concentration of cell-impermeant molecules. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, maintaining blood circulation and oxygenation of tissues, and extending the “Golden Hour” for traumatic and/or hemorrhagic shock patients. In addition, compositions comprising PEG-20k and methods of their use for preserving and/or reanimating harvested organs ex vivo for lengthy periods of time (e.g. at least about 8-24 hours) are also provided.
Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of mictruitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
Type:
Application
Filed:
June 30, 2015
Publication date:
June 1, 2017
Inventors:
Stephen CALTABIANO, Eliot OHLSTEIN, Stewart MCCALLUM
Abstract: Administration of isoleucine, leucine and valine is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. This method is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment.
Type:
Application
Filed:
February 13, 2017
Publication date:
June 1, 2017
Applicants:
EA Pharma Co., Ltd., NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Abstract: The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.
Type:
Application
Filed:
September 8, 2016
Publication date:
June 1, 2017
Applicant:
N.V. Nutricia
Inventors:
Eline Marleen VAN DER BEEK, Marieke ABRAHAMSE-BERKEVELD, Annemiek Lidewij SCHIPPER, Gelske SPEELMANS
Abstract: The present invention relates to the use of leukotriene B4 to enhance the response of Toll-like receptor (TLR), RIG-I-like receptor (RLR), and NOD-like receptor (NLR) when stimulated simultaneously with respective proper ligands. The use in combination of LTB4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders.
Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects.
Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
Abstract: Pharmaceutical compositions comprising an ester anesthetic and a cholinesterase inhibitor have been found to exhibit surprising and beneficial results in achieving a long-acting nerve block for example when administered to an interfascial plane or a peri-neural location in a subject. Such pharmaceutical compositions may also contain an amide anesthetic. Pharmaceutical compositions and methods of using such compositions as described herein provide a surprising and unexpected duration of pain control and a reduced need for the use of narcotics.
Abstract: The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.
Type:
Application
Filed:
December 1, 2016
Publication date:
June 1, 2017
Inventors:
Stanley Leon HAZEN, Jose Carlos GARCIA-GARCIA, George Franklin GERBERICK, John August WOS, David Thomas STANTON, Thomas Alfred INGLIN, Michael REILLY, Angela Jane DEUTSCH, Jodie Michele REED, David Blair CODY
Abstract: The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
Type:
Application
Filed:
February 13, 2017
Publication date:
June 1, 2017
Inventors:
Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
Abstract: The invention relates to a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, as well as pharmaceutical composition comprising the compound together with a pharmaceutically acceptable excipient, vehicle or carrier, for use in the treatment of cancer.
Type:
Application
Filed:
November 29, 2016
Publication date:
June 1, 2017
Inventors:
Zita Bognár, Balázs Sümegi, Ferenc Gallyas, JR., Kálmán Tóth
Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant. Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.
Type:
Application
Filed:
November 30, 2015
Publication date:
June 1, 2017
Inventors:
Kam Wai Wong, Yuen Kwan Law, Thomas Efferth, Onat Kadioglu, Liang Liu
Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Applicants:
THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Applicants:
THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
Abstract: This invention relates to the use of rotigotine for the effective treatment of Restless Leg Syndrome (RLS) as well as to a rotigotine-containing transepicutaneous pharmaceutical composition, provided in particular in the form of an acrylate- or silicone-based Transdermal Therapeutic System (US) having a surface area of 2.5 to 20 cm2 and containing 0.1 to 3.15 mg/cm2 rotigotine as its active component against the Restless Leg Syndrome, said system leading in the human Restless Leg Syndrome condition to an improvement, compared to a placebo treatment, by 2 or more units on the International Restless Leg Syndrome Study Group (IRLSSG) scale after administration over a period of eight days.
Abstract: A kit, optionally for treating a patient having ASD, is disclosed. The kit includes at least one first package and at least one second package. The first package contains an alpha-2 adrenergic agonist in an extended release dosage form. The second package contains inositol.
Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Type:
Application
Filed:
February 10, 2017
Publication date:
June 1, 2017
Inventors:
Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
Type:
Application
Filed:
May 26, 2015
Publication date:
June 1, 2017
Applicant:
Purdue Pharmaceutical Products L.P.
Inventors:
Thomas Jorg Mehrling, Enrique Maria Ocio
Abstract: The present invention provides an antiperspirant which can effectively and safely control perspiration. The antiperspirant in accordance with an aspect of the present invention contains a mTOR inhibitor. The mTOR inhibitor can be rapamycin, a rapamycin derivative, or the like, and the antiperspirant can be used against hyperhidrosis and the like.
Type:
Application
Filed:
June 25, 2015
Publication date:
June 1, 2017
Inventors:
Mari KANEDA, Ichiro KATAYAMA, Hiroyuki MUROTA, Saki MATSUI
Abstract: The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin.
Type:
Application
Filed:
November 3, 2016
Publication date:
June 1, 2017
Inventors:
Pam Golden, Anthony Fodor, Enoch Bortey, William Forbes
Abstract: Pharmaceutical compositions comprising a beta-lactam compound selected from cefepime, sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.
Abstract: The present invention features compositions and methods for treatment of snoring. We describe compositions comprising an antihistamine or a pharmaceutically acceptable salt thereof and one or more dietary supplements or pharmaceutically acceptable salts thereof. The compositions can be administered to a subject suffering from snoring.
Abstract: The combination of gabapentin with lysine clonixinate (CLG) makes it possible to relieve neuropathic pain caused both by diabetic neuropathy and by an injury to the nerve. The CLG combination produces a synergy in the antiallodynic effect, when the allodynia has been generated by direct mechanical damage to nervous tissue or when it has been produced as a result of a diabetic pathology. The therapeutic effect of the CLG combination is 3 to 11 times greater than the effect of each of the drugs separately. The CLG combination is safe, because it shows no adverse effects on motor activity or alterations in neurological parameters nor damage to the liver or kidney.
Type:
Application
Filed:
June 16, 2014
Publication date:
June 1, 2017
Inventors:
Graciela de los Ángeles AGUILERA SUÁREZ, Carmen Miguel GÓMEZ SÁNCHEZ, Martha Rosaura JUÁREZ LORA